Alnylam Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ALNY Nasdaq 2834 http://www.alnylam.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alnylam Pharmaceuticals, Inc.

Alnylam to Host Fifth Annual “RNAi Roundtable” Webcast Series - Jun 21st, 2018 5:00 am
Caladrius Biosciences’ Stock Price Rose 67% on June 19 - Jun 20th, 2018 8:09 am
Alnylam Expands Senior Leadership Team with Two Key Appointments - Jun 20th, 2018 5:00 am
Alnylam to Report New Clinical Results for Patisiran at the 4th Congress of the European Academy of Neurology - Jun 15th, 2018 5:00 am
Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Intercept Pharmaceuticals - Jun 13th, 2018 6:20 am
Over 700 Alnylam Employees Volunteer at the Company’s 4th Annual “Helping Hands” Community Service Day - Jun 12th, 2018 6:00 am
Wired News – Alnylam Pharma Presented New Encouraging Results from Phase-1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type-1 - Jun 12th, 2018 5:30 am
Alnylam Reports Positive Data on Lumasiran in Renal Disease - Jun 11th, 2018 2:49 pm
Stock Performance Review on Alder Biopharma and Three Other Biotech Stocks - Jun 11th, 2018 5:10 am
See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc. - Jun 8th, 2018 6:06 am
Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1) - Jun 8th, 2018 5:00 am
3 Top Biotech Stocks to Buy in June - Jun 4th, 2018 9:36 am
Alnylam Receives Orphan Drug Designation from the United States Food & Drug Administration for ALN-TTRsc02, a Subcutaneously Delivered Investigational RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis - Jun 4th, 2018 5:00 am
Why Is Alnylam (ALNY) Up 12.6% Since Its Last Earnings Report? - Jun 4th, 2018 4:25 am
Better Buy: Bellicum Pharmaceuticals, Inc. vs. Alnylam Pharmaceuticals, Inc. - Jun 3rd, 2018 5:17 am
The Upside Potential in Editas Medicine Stock - May 29th, 2018 6:15 am
Alnylam to Webcast Presentations at Upcoming June Investor Conferences - May 29th, 2018 5:00 am
Do Alnylam Pharmaceuticals’ Cash Flows Look Healthy? - May 25th, 2018 5:30 am
What Do Alnylam’s Valuations Indicate? - May 24th, 2018 2:00 pm
How Has Alnylam Pharmaceuticals Performed Financially? - May 24th, 2018 2:00 pm